Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide
Autore:
Friedhoff, LT; Cullen, EI; Geoghagen, NSM; Buxbaum, JD;
Indirizzi:
CUNY Mt Sinai Sch Med, Dept Psychiat, Lab Mol Psychiat, New York, NY 10029USA CUNY Mt Sinai Sch Med New York NY USA 10029 ychiat, New York, NY 10029USA CUNY Mt Sinai Sch Med, Dept Neurobiol, New York, NY 10029 USA CUNY Mt Sinai Sch Med New York NY USA 10029 obiol, New York, NY 10029 USA Andrx Corp, Aura Labs Inc, Hackensack, NJ 07601 USA Andrx Corp HackensackNJ USA 07601 ura Labs Inc, Hackensack, NJ 07601 USA
Titolo Testata:
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
fascicolo: 2, volume: 4, anno: 2001,
pagine: 127 - 130
SICI:
1461-1457(200106)4:2<127:TWCLDS>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALZHEIMERS-DISEASE; CHOLESTEROL; DEMENTIA; RISK;
Keywords:
beta-amyloid; A beta; Alzheimer's disease; controlled-release lovastatin; clinical trial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Buxbaum, JD CUNY Mt Sinai Sch Med, Dept Psychiat, Lab Mol Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA CUNY Mt Sinai Sch Med 1 Gustave L Levy Pl,Box 1230 New York NY USA 10029
Citazione:
L.T. Friedhoff et al., "Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide", IN J NEUROP, 4(2), 2001, pp. 127-130

Abstract

The deposition of beta -amyloid (A beta) in neuronal plaques is believed to be crucial for the initiation and progression of Alzheimer's disease (AD). Studies in vitro have shown that inhibiting cholesterol metabolism with lovastatin, or its active metabolite lovastatin acid, lowers A beta production. To examine the effects of lovastatin on A beta in vivo, human subjects who had elevated low-density lipoprotein cholesterol were treated during a double-blind, randomized, placebo-controlled study with 10, 20, 40 or 60 mgonce-daily doses of a controlled-release formulation of lovastatin, or matching placebo. Serum A beta concentrations were measured before and after up to 3 months of treatment. Mean and median changes from baseline in serum A beta concentrations showed a dose-dependent decrease, and analysis of variance indicated that treatment was statistically significant (p < 0.0348). Differences between the 40- and 60-mg dose groups and placebo were statistically significant (Dunnett's p less than or equal to 0.05).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/05/20 alle ore 14:29:45